Indian stocks: Visit www.stage2stocks.com →

SELLAS Life Sciences Group, Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, SELLAS Life Sciences Group is in Stage 3, the topping phase, now in week 4 (since Sep 29, 2026). It closed at $11.35, 26.6% below its 52-week high and above its 200-day average, which is rising.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. More about the company

$11.35
-6.51% today
$2.3B · Mid cap
Market Neutral — Fading

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SLS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 30w
S2 19w
S2 41w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 30w → S1 6w → S2 10w → S3 10w → S2 7w → S3 3w → S4 12w → S1 5w → S2 4w → S3 3w → S2 19w → S3 4w → S2 4w → S3 4w → S2 41w → S3 3w current
Total tracked: 166 weeks across 16 stage runs.

SLS among Biotechnology3rd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
vs 52W High
-26.6%
$1.39 lo$15.46 hi
26.6% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 4
1w13w26w
Week 4, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
35.7%
200 DMA: $8.36 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.98x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-1.5%
3M
+0.3%
6M
+144.6%
YTD
+160.9%
1Y
+494.2%
Scan Membership
Breakout Watch
Latest: 2025-03-20
8 appearances in last 60 days. First seen: 2020-11-23.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 4 · Vol 0.98x
2026-10-21S3
Wk 4 · Vol 0.85x
2026-10-20S3
Wk 4 · Vol 1.57x
2026-10-19S3
Wk 3 · Vol 0.86x
2026-10-16S3
Wk 3 · Vol 2.52x
2026-10-15S3
Wk 3 · Vol 0.74x
2026-10-14S3
Wk 3 · Vol 0.75x
2026-10-13S3
Wk 3 · Vol 1.01x
2026-10-12S3
Wk 2 · Vol 0.63x
2026-10-09S3
Wk 2 · Vol 0.66x
2026-10-08S3
Wk 2 · Vol 0.66x
2026-10-07S3
Wk 2 · Vol 0.48x
Moving averages & range
50 DMA
$12.42
200 DMA
$8.36
52W High
$15.46
52W Low
$1.39
5D Low
$9.98
Resistance levels (recent highs)
20d High
$12.41
60d High
$15.46
120d High
$15.46
250d High
$15.46
Next resistance
+9.3%
to 20d High
ROE
-39.6%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 16.6

SELLAS Life Sciences Group: quick answers

What stage is SELLAS Life Sciences Group in?

As of Oct 22, 2026, SELLAS Life Sciences Group (SLS) is in Stage 3, the topping phase. It entered Stage 3 on Sep 29, 2026 and is in week 4. What the four stages mean

Is SELLAS Life Sciences Group in an uptrend?

Its uptrend has stalled. SELLAS Life Sciences Group is in Stage 3, the topping phase that follows an advance. It trades 35.7% above its 200-day average, which is rising.

How far is SELLAS Life Sciences Group from its 52-week high?

SELLAS Life Sciences Group closed at $11.35 on Oct 22, 2026, 26.6% below its 52-week high of $15.46. Its 52-week low is $1.39.

How has SELLAS Life Sciences Group performed over the past year?

As of Oct 22, 2026, SELLAS Life Sciences Group is up 494.2% over the past year and up 160.9% so far in 2026.

Which sector and industry is SELLAS Life Sciences Group in?

SELLAS Life Sciences Group is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.